- Partnership to jointly establish state-of the art center for molecular imaging and clinical development of targeted radionuclide therapy.
- Objective to accelerate precision medicine with more targeted treatment in oncology and other therapy areas.
Copenhagen, Denmark – December 14, 2021 - GE Healthcare and Minerva Imaging have announced a strategic partnership with the aim to bring targeted radionuclide therapies (Theranostics) faster to the market. Radionuclide therapy is a form of precision medicine where a radioactive substance is administered through the bloodstream to specifically target cancer cells and irradiate them. This helps reduce potential side effects compared to traditional cancer therapies. Recent years have seen strong growth in targeted radionuclide therapies.
Adding to its 2,000 m2 R&D site, Minerva Imaging will open a new facility in 2022 and expand its R&D footprint by 50%. The Denmark-based company expects to employ over 100 people at the new facility by the end of 2022. The expansion will give the company the extra capacity it needs to meet growing demand in the radionuclide therapy sector.
The partnership with GE Healthcare is designed to facilitate the success of Minerva Imaging’s growth plans by establishing capabilities for in-house production of isotopes and CDMO services for radiopharmaceuticals. Minerva Imaging will be using cutting-edge technology from GE Healthcare to optimize new radiopharmaceuticals, including a cyclotron – a type of particle accelerator used to produce isotopes.
GE Healthcare will support Minerva Imaging to set up Good Manufacturing Practice (GMP) production in the new facility. This will help ensure high quality products for Minerva Imaging’s clients which, in turn, will support the best possible outcomes for patients. GE Healthcare and Minerva Imaging will work in partnership to innovate and optimize manufacturing protocols for new radioisotopes by sharing knowledge and expertise related to technological innovation.
Simon McGuire, Northern Europe Regional General Manager at GE Healthcare, said: “Minerva Imaging could with this expansion become an important player in clinical development of life-saving medicines. GE Healthcare has, for many years, through our Imaging and Pharmaceutical Diagnostics businesses, been building technology and radiopharmaceuticals that help enable precision health. Now, together with Minerva Imaging, we have the opportunity to further accelerate efforts in this space.”
Carsten Nielsen, CEO and co-founder of Minerva Imaging, said: “Partnering with a global leader like GE Healthcare is a major milestone for Minerva Imaging. Together, we have the capacity to work on more innovative therapies, accelerate their route to market and treat more patients with the targeted therapy. There are only winners in a collaboration like this.”
GE Healthcare offers medical practitioners the tools and support they need to improve patient-centered care and advance the practice of precision medicine. Through this partnership and a variety of other partnerships and solutions, GE Healthcare aims to further reinforce its role as a core partner in improving cancer care.
About GE Healthcare:
GE Healthcare is the $17 billion* healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
About Minerva Imaging ApS:
Minerva Imaging is a scientifically driven CRO founded in 2011. The company focuses on the use of advanced models and molecular imaging for translational research and drug development. Minerva Imaging engages with its clients to understand their scientific questions and discuss how its methods and capabilities can provide answers. The company’s competences build on more than two decades of research within oncology, cardiovascular disease and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.
 Research and Market. Global Theranostics Markets Report 2020: Oncology Segment Market for Theranostics Should Grow from $73.1 Billion in 2020 to $119.7 Billion by 2025. Published in 2020.